- September 4, 2018
- Posted by: admin
- Category: Uncategorized
Big Pharma is in a rut. The industry keeps spending more and yet making fewer scientific breakthroughs.But help is on the way.
GlaxoSmithKline recently announced a radical change in R&D spending. The British drug giant will refocus on data analytics, and the link between the immune system and human disease.
It is harbinger of things to come. It is also a big opportunity for investors.
GSK is trying to catch bigger trends. By studying the genetic profiles of patients with diseases, scientists are starting to understand what makes humans ill in the first place.
Meanwhile, information technology is accelerating at an exponential rate. Every day, researchers use advances in machine learning and artificial intelligence to see patterns in data that were invisible only decade ago.
Too often, we believe these advances are limited to self-driving vehicles or automated factories. In reality, this progress applies to a wide variety of sectors.
Drug discovery is especially ripe for disruption because it has not evolved in decades.
In “The Future Awakens,” a November 2017 research study by the Deloitte Center for Health Solutions, analysts see big changes not even five years from now.
They posit that, by 2022, medicine will be predictive, preventive (based on risk), personalized and participatory.
It is a wild vision of the future …
• Computational biologists in hoodies and jeans will build personalized drug treatments based on what they know about the patient’s individual genomic makeup .
• And behind the scenes, data scientists will use AI to look for previously unseen biomarkers in algorithmic models.
It is a view that dovetails with a recent GSK promotional video. The company is promising to use genetic insights, its growing understanding of the immune system and data analytics at scale.
They want to deliver the next generation of scientific breakthroughs and, in some cases, cures.
GSK took an important step in that direction with a new $300 million investment in 23andMe, a personal genomics company based in Mountain View, Calif. To date, this Silicon Valley company has collected genomic information for 5 million people — a huge data hoard.
The companies will initially collaborate on a Parkinson’s research project.
Read More Here
Article Credit: Forbes
The post Big Data Is Remaking Big Pharma appeared first on erpinnews.